Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Transcutaneous posterior tibial nerve stimulation vs solifenacin for overactive bladder in women
2017-000605-20Phase 4Active
- Sponsor
- Fundación para la Formación e Investigación Sanitaria
- Start
- May 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of solifenacin in overactive bladder (OAB) (2 arms), sponsored by Fundación para la Formación e Investigación Sanitaria. Primary endpoint: Symptom improvement ≥50% in SVHI signs at 3 months. Started May 2017; status: active.
02
Drugs
solifenacin
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on 2017-000605-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000605-20.